Hypoxia Inducible Factor-2 Inhibitor Belzutifan For Vhl Treatment | Family Weekend 2024

Hypoxia Inducible Factor-2 (HIF-2) Inhibitor Belzutifan for VHL Treatment | Family Weekend 2024

Belzutifan: Managed access treatment for Von Hippel-Lindau (VHL) disease

National Institute for Health and Care Excellence (NICE)

WELIREG (belzutifan)- treatment of adult patients with von Hippel-Lindau (VHL) disease

Pharmacy Talk USA

The role of pembrolizumab and HIF-2α inhibitors in renal carcinoma

VHL Breakthrough: An Expert Discussion

Belzutifan real-world vs clinical trial data: comparing efficacy and safety in VHL-associated tumors

Opening Remarks and Special Lecture on Belzutifan Development | Medical Symposium 2024

Promising real-world outcomes of belzutifan in VHL-associated tumors

Practice Update: Updated Results of Belzutifan for Advanced RCC

Belzutifan as a non-invasive treatment option for VHL-associated tumors

Belzutifan for Von Hippel-Lindau syndrome

LITESPARK-004: ESA use in VHL disease-associated RCC

Phase I/II tral of NKT2152, an HIF-2α inhibitor, in pre-treated accRCC

Belzutifan - The New Kid on the Block

Dr Prasant Nayak, Urologist, AIIMS, Bhubaneswar

Systemic Therapy with Belzutifan Approved for Von Hippel Lindau-associated Cancers

Novel Von Hippel-Lindau syndrome therapies inhibiting HIF-2α

Clear cell RCC: VHL/HIF pathway

Von Hippel-Lindau disease (Year of the Zebra 2024)

Osmosis from Elsevier

David Braun, MD, PhD, offers opinion on the role of HIF-2α inhibitors in ccRCC

Clinical Management of VHL Tumors - Systemic Agents for VHL | Medical Symposium 2024